GlassScriptPhysician profile
Logan T Mendheim
NPI 1871042226
$10,427.24
in general payments reported to CMS, 2019-2025
29 companies · $745 in 2025
The $745 reported for 2025 was more than what 75% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,508 · 2022: $3,083 · 2023: $2,456 · 2024: $1,635 · 2025: $745.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,836.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,836.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,638.66 | 2022-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Abbvie INC. | $1,356.54 | 2021-2025 | |
| Vanda Pharmaceuticals INC. | $1,014.77 | 2021-2025 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $930.63 | 2021-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $816.88 | 2021-2025 | Trintellix |
| Axsome Therapeutics, INC. | $685.11 | 2022-2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $643.91 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $636.78 | 2021-2024 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $513.54 | 2022-2024 | Austedo Xr, Uzedy, Austedo |
| Lundbeck LLC | $424.62 | 2021-2025 | Rexulti |
| Sunovion Pharmaceuticals INC. | $247.48 | 2021 | |
| Supernus Pharmaceuticals, INC. | $231.59 | 2021-2023 | Qelbree |
| Almatica Pharma LLC | $231.14 | 2022-2024 | Loreev Xr, Sertraline Hcl |
| Neurocrine Biosciences, INC. | $221.24 | 2022-2024 | Ingrezza |
| Corium, LLC | $165.53 | 2021-2023 | Azstarys |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $153.39 | 2021-2024 | Adzenys Xr-Odt |
| Avanir Pharmaceuticals, INC. | $133.29 | 2022 | |
| Bausch Health US, LLC | $81.44 | 2022-2023 | Aplenzin |
| Eisai INC. | $63.13 | 2021-2022 | |
| Indivior INC. | $56.58 | 2021 | |
| Noven Therapeutics, LLC | $50.91 | 2023-2024 | Xelstrym, Secuado |
| Adlon Therapeutics L.P. | $24.50 | 2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $16.36 | 2025 | Rejoyn |
| Alfasigma USA, INC. | $16.28 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $16.15 | 2024 | Cobenfy |
| Idorsia Pharmaceuticals US INC | $15.45 | 2023 | Quviviq |
| Brainsway USA INC | $15.10 | 2025 | Deep Tms System |
| Tris Pharma INC | $13.38 | 2024 | Dyanavel Xr |
| Astrazeneca Pharmaceuticals LP | $12.86 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Logan Mendheim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.